Capitainer enters collaboration with the University of Florida and Dr. Timothy Garrett
The goal is to accelerate method development for implementation of Capitainer’s qDBS-sampling for clinical diagnostics in the US and globally
Stockholm, Sweden, October 5, 2022: Swedish medtech start-up Capitainer today announced that the company has entered a collaboration agreement with Timothy J. Garrett Laboratory, College of Medicine, University of Florida. Dr. Tim Garrett is one of the leading experts and an authority in the US when it comes to applying mass spectrometry within the area of metabolomics and its clinical applications. He has a huge network of collaborating partners including clinics at UF and externally.
The aim with the new collaboration is to accelerate method development and pave the way for broader use of the qDBS technology in clinical diagnosis. Capitainer has shown to have a superior product for self-sampling with excellent usability and volumetric accuracy and precision. However, there is a shortage of clinical laboratories and methods for microsamples collected at home, and the initiated collaboration will accelerate the development of necessary laboratory tools.
“I’m excited about developing precision diagnostics that will enable future health care and look forward to this collaborative effort,” said Dr. Timothy Garrett, an associate professor in the university’s Department of Pathology, Immunology and Laboratory Medicine. “Our success would mean a changed landscape for medical diagnostics.”
In the collaboration, Dr. Donald H. Chace, Capitainer’s representative for North Americas will also bring his wealth of experience when it comes to analysing dried blood spot, covering Neonatology, Clinical Chemistry, Newborn Screening, Mass Spectrometry and Forensic Science as well as his lab’s resources to the table. This, combined with Garrett’s access to a network of clinics for collaboration will, Capitainer believes, create the ideal foundation for new testing method development and validation within clinical diagnostics.
“I have known Tim now for the better part of ten years, discussing clinical chemistry, metabolomics, and participating in short course, lectures and education clinical chemistry and science in general. Now we can together put our ideas into action, developing then validating new clinical analysis in areas of screening, diagnostics and metabolomics research starting at the 1st Step. A new, improved, more precise, protected dried blood spot.” says Dr. Chace.
Foundation in place
Over the last two years, Capitainer’s qDBS-sampling technology has been validated in real world population studies. No less than 97% of the cards sent back by regular mail to the lab met the approved quality standard for analysis. Additionally, in a major study published last week in Clinica Chimica Acta on the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU), demonstrated conclusively the superiority of Capitainer’s solution over conventional cards and competition, https://www.sciencedirect.com/science/article/pii/S0009898122012566.
For more information visit www.capitainer.se
Contacts
Christopher Aulin, CEO t: +46 708 977 577 e:aulin@capitainer.se
Media
Richard Hayhurst/Ola Bjorkman
Notes to editors
About Timothy J. Garrett Laboratory
Garrett’s lab focuses on the application and development of mass spectrometry for clinical research covering many areas such as cancer, the microbiome, rare diseases, and autoimmune disorders. The flexibility that mass spectrometry offer enables simultaneous measurement of substances in excess of 2000 substances or in other cases a smaller subset of metabolites. The wealth of experience from method development and biomarker research is a perfect foundation for establishing robust methods, targeted at one or several measurements in the same sample.
https://garrettlab.pathology.ufl.edu/
About Capitainer
Captainer AB is a Swedish medtech company founded in 2016. Capitainer is developing intelligent solutions for Dried Blood and Plasma Spot sampling with the market’s best volume accuracy serving several market segments, including but not limited, to Therapeutic Drug Monitoring, Biomarkers, Drug Development and Drugs of Abuse and Doping. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.
